The Federal Court previously found that Apotex and Cobalt infringed Bayer’s valid patent for an oral contraceptive composition combining drospirenone and ethinyl estradiol (Bayer’s YAZ and YASMIN) (2016 FC 1013, as reported here). The Federal Court subsequently held that Bayer was entitled to elect between damages and an accounting of Apotex’s profits (2016 FC 1192, as reported here). In so holding, the Federal Court disagreed with Apotex’s argument that it, rather than Bayer, should be entitled to elect whether Bayer should be limited to recovering Apotex’s profits. The Federal Court of Appeal dismissed Apotex’s appeal of the latter decision, holding that “the proposition that the infringer of a patent can determine the remedy to which the patentee is entitled is an astounding proposition” (Apotex Inc v Bayer Inc, 2018 FCA 32). The Federal Court of Appeal affirmed that, under the Patent Act, a successful patentee always has a right to its damages, and only it has the right to elect an accounting of profits, subject to the court’s discretion.
Related Publications & Articles
-
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More -
2025 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories.Read More